Search

Displaying results 4971 - 4980 of 10000 in total
  1. Drug

    PRLX 93936

    go.drugbank.com/drugs/DB06098
    Investigational

    PRLX 93936 is selectively toxic to cancer cells.

  2. Drug

    Bradanicline

    go.drugbank.com/drugs/DB06090
    Investigational

    Bradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).

    Categories: Heterocyclic Compounds, 2-Ring
  3. Drug

    Annamycin

    go.drugbank.com/drugs/DB06420
    Investigational

    Synonyms: 2'-Iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicinCategories: P-glycoprotein inhibitors
  4. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  5. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental

    Categories: Heterocyclic Compounds, 2-Ring
  6. Drug

    Prajmaline

    go.drugbank.com/drugs/DB13555
    Experimental

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ia
  7. Drug

    8-anilinonaphthalene-1-sulfonic acid

    go.drugbank.com/drugs/DB04474
    Experimental

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 1-Anilino-8-naphthalenesulfonate, 1-anilino-8-naphthalenesulfonic acid
  8. Drug

    Strychnine

    go.drugbank.com/drugs/DB15954
    Experimental

    Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 2-Ring
  9. Drug

    BL-1020

    go.drugbank.com/drugs/DB05687
    Investigational

    BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).

    Categories: Heterocyclic Compounds, 3-Ring
  10. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … of resistance mutations, particularly the solvent front G2032R substitution, and progression of disease in the brain.